Romeo Gabriel Mihăilă, A Look at the Future Hemophilia A Treatment, IJPPE Volume 11, International Journal of Pharmacology, Phytochemistry and Ethnomedicine (Volume 11)
    The current treatment of patients with hemophilia A is safer and more effective than the previous one. Prophylactic substitution involves repeated intravenous administration of plasma-derived factor VIII or recombinant factor VIII products, with inconveniences and possible adverse effects. The occurrence of inhibitors requires the administration of activated prothrombin complex concentrate or activated factor VII - an expensive treatment. The immune tolerance induction is the ideal treatment for patients with high titres of inhibitors - the only potential way to eliminate inhibitors and very expensive. For these reasons, the medical world is interested in the advances that scientific research is doing in the field of new molecules without the inconveniences of current substitution therapy and which could replace it in the future. The purpose of this article is to briefly review the new therapeutic possibilities for patients with hemophilia A, which can prevent potential extraarticular bleedings, avoid the occurrence of inhibitors, and have as few adverse effects as possible.
    Emicizumab, Haemophilia A, Inhibitors, Moroctocog Alfa, Plasma-Derived Factor VIII, Recombinant Factor VIII